Fajar Husen
@stikesbinaciptahusada.ac.id
Medical Laboratory of Technology
College of Health Science of Bina Cipta Husada
Lecturer of Medical Laboratory of Technology
EDUCATION
Bachelor Degree of Biology of Jenderal Soedirman University (UNSOED)
Master of Science of Biology (Microbiology) of Jenderal Soedirman University (UNSOED)
RESEARCH INTERESTS
Microbiology, Immunology, Medical Mycology, Histology
FUTURE PROJECTS
SOYBEAN SELECTION AGAINST CERCOSPORA LEAF BLIGHT DISEASE CAUSED BY CERCOSPORA KIKUCHII BASED ON ANATOMICAL RESISTANCE
Soybean (Glycine max L. Merr.) is the third food crop commodity after rice and maize in Indonesia. This plant is also known as the most important source of vegetable protein, which is relatively inexpensive, but a decrease in soybean productivity can occur due to infection with disease-causing pathogens, one of is Cercospora kikuchii which causes Cercospora leaf blight (CLB). The research objectives were to determine the anatomical resistance and disease severity of soybean cultivars against CLB. The method was an experiment with a completely randomized design (CRD) factorial pattern; factor 1 being soybean cultivars (Dering, Slamet, Grobogan, Wilis) and factor 2, namely pathogen inoculation (0 conidiospores/mL and 105 conidiospores/mL). Anatomical method preparations using paraffin, staining with 1% safranin. Disease criteria are based on the council of scientific and industrial research (CSIR) assessment method. Data were analysis used analysis of variance (p<0.05)
Applications Invited
Anatomical resistance
Ethanol extract of the mushroom Coprinus comatus exhibits anti-diabetic and antioxidant activities in streptozotocininduced diabetic rats
To identify the benefits of ethanol extracts of the C. comatus fruit body in streptozotocin-induced hyperglycemic rats by evaluating their blood glucose, glycosylated hemoglobin (HbA1c), insulin, glucagon-like peptide-1 (GLP-1), dipeptidyl peptidase-4 (DPP-4), and glutathione (GSH) levels, with and without extract administration
Applications Invited
Antidiabetic effect
Antioxidant Activities and Properties of Coprinus comatus Mushroom Both Mycelium and Fruiting Body Extracts In Streptozotocin-Induced Hyperglycemic Rats Model
The study evaluated in vitro and in vivo treatments to evaluate antioxidant effect and activity of C. comatus. The in vivo treatment was conducted using six groups of Wistar rats (n = 24). Group 1 healthy control (HC), groups 2–6 received 45 mg/Kg BW of streptozotocin once, group 2 just streptozotocin-induced (NC), group 3 was given 45 mg/kg BW of metformin (PC), groups 4–6 were given 250 (T1), 500 (T2), and 750 mg (T3) of C. comatus extract for 14 days, and the in vitro was conducted using an antioxidant oxidant assay. Data were analyzed using analysis of variance and Duncan’s multiple-range tests
Applications Invited
Antioxidant supplement
Scopus Publications
Scholar Citations
Scholar h-index
Scholar i10-index
Scopus Publications
Nuniek Ina Ratnaningtyas and Fajar Husen
Veterinary World
Background and Aim: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent joint inflammation and systemic immune dysregulation. The current pharmacological treatments, primarily synthetic drugs, often present adverse effects and long-term toxicity. This study explores the therapeutic potential of Coprinus comatus nanogels as a novel herbal formulation with antiarthritic and anti-inflammatory properties in a Complete Freund’s Adjuvant (CFA)-induced rat model of RA. The study aims to evaluate the efficacy of C. comatus nanogels in reducing pro-inflammatory cytokine levels, antibody production, paw edema, and arthritis indices and to assess their potential as a safer alternative to conventional RA therapies. Materials and Methods: Twenty-four male Wistar rats were randomized into six groups: Healthy control, negative control (CFA-induced without treatment), positive control (sodium diclofenac 0.012 g/mL), and three treatment groups (TG1, TG2, and TG3) receiving 250, 500, and 750 mg/kg C. comatus nanogels, respectively. Oral treatments were administered for 30 days. Pro-inflammatory cytokines (tumor necrosis factor-alpha [TNF-α], interleukin [IL]-6, IL-1β), antibodies (immunoglobulin [Ig]G, IgE), cyclooxygenase-2 (COX-2) enzyme activity, paw edema, and arthritis indices were measured using enzyme-linked immunosorbent assay and standard methods. Statistical analyses were conducted using one-way analysis of variance. Results: The 750 mg/kg dose of C. comatus nanogels significantly reduced TNF-α (17.71%), IL-1β (19.83%), and IgE (23.91%) levels. The 250 mg/kg dose exhibited the highest reductions in IL-6 (30.88%) and COX-2 (16.54%) levels. TGs demonstrated a 27.75% reduction in paw edema and a 45.45% reduction in arthritis indices. Key bioactive compounds contributing to these effects included flavonoids, polyphenols, triterpenoids, and β-glucans. Conclusion: C. comatus nanogels demonstrated promising anti-inflammatory and antiarthritic properties, suggesting their potential as an alternative herbal treatment for RA. Further studies are recommended to explore the long-term safety and clinical applicability of C. comatus nanogels in human RA management. Keywords: anti-inflammatory, Coprinus comatus, cytokine reduction, herbal medicine, nanogels, rheumatoid arthritis.
Nuniek Ina Ratnaningtyas, Fajar Husen, Nur Fitrianto, and Juni Safitri Muljowati
Begell House
<i>Pleurotus cystidiosus</i> (abalone oyster mushroom) is an edible species that belongs to the group of woody mushrooms from the Pleurotaceae family. This mushroom contains bioactive compounds such as alkaloids, flavonoids, polyphenols, rutin, quercetin, and triterpenoids that act as antidiabetics and anti-inflammatory agents. Research on using <i>P. cystidiosus</i> mushrooms cultivated in Cianjur, West Java, is rare. These mushrooms are only used as daily food; besides that, their activity as antidiabetic and anti-inflammatory has never been reported or investigated. This research aimed to determine and examine the potential of <i>P. cystidiosus </i>mushroom micro encapsulant as an antidiabetic and anti-inflammatory agent. The research method was an experiment using 30 male white rats of <i>Rattus norvegicus</i> with 200 g body weight (BW) that induced streptozotocin (STZ) dose of 45 mg/kg BW, and divided into 6 groups: HGCt (healthy control, no treatment), NGCt (negative control, induced STZ only), PGCt (given metformin 45 mg/kg BW), TGM1 (given microencapsulant 150 mg/kg BW), TGM2 (given microencapsulant 200 mg/kg BW), TGM3 (given microencapsulant 250 mg/kg BW) for 15 d. The research approach was post-test-only with the control group and complete randomized design (CRD). The results showed that <i>P. cystidiosus</i> microencapsulant contained polyphenols (3.61 mg), flavonoids (2.21 mg), alkaloids (5.51 mg), amino acids (3.67), and triglycerides (3.78 mg). Microencapsulant administration was also able to reduce blood glucose levels by &#62; 50&#37;, increase insulin hormone by &#62; 25&#37;, increase GLP-1 hormone levels by &#62; 60&#37;, reduce DPP-4 enzyme levels by &#62; 18&#37;, also reduce inflammatory mediators TNF-&alpha; &#62; 22&#37; and IL-1&beta; &#62; 56&#37;. Based on these results, <i>P. cystidiosus</i> microencapsulation has the potential to be developed as an anti-diabetic and anti-inflammatory nutraceutical.
Nur Fitrianto, Siti Samiyarsih, Fajar Husen, Andri Frediansyah, and Galang Anahatta Hidayat
AIP Publishing
Nuniek Ina Ratnaningtyas, Fajar Husen, and Nur Fitrianto
Begell House
Lingzhi or reishi mushroom, Ganoderma lucidum, is a medicinal mushroom quite widely developed as herbal medicine because it has acted as an anticancer, antitumor, antioxidant, and anti-inflammatory. The active mycochemical compounds of G. lucidum mushrooms, such as flavonoids and polysaccharides, can suppress the release of pro-inflammatory cytokines and prevent lipid peroxidation due to oxidative stress. Rheumatoid arthritis (RA) is an autoimmune disease where the exact cause is unknown, and RA prevalence continues to increase yearly. In patients with RA, joint damage and inflammation occur. This study aims to evaluate the effectiveness of G. lucidum nanogels as anti-arthritis, anti-inflammatory, and antioxidative. The research method was a true experiment using a control group and treatment group that randomly assigned, using 24 male Wistar rats (Rattus norvegicus) induced with complete Freund's adjuvant (CFA) 0.1 mL. The rats were divided into six groups; healthy control/HCt (did not receive the treatment), negative control/NCt (induced by CFA), and positive control/PCt (given 0.012 diclofenac sodium). TG1 (given 250 mg G. lucidum nanogels), TG2 (given 500 mg G. lucidum nanogels), TG3 (given 750 mg G. lucidum nanogels). IgG, eNOS, IL-1β, COX-2, NOS, TNF-α, and IL-6 parameters were measured using ELISA, and the data obtained were analyzed by one-way ANOVA using SPSS (P < 0.05). The results showed that administering G. lucidum nanogels significantly reduced IgG, NOS, TNF-α, COX-2, IL-1β, and IL-6 and increased eNOS levels. The anti-inflammatory and antioxidative activities in suppressing pro-inflammatory cytokines and increasing eNOS levels prove that the nanogel extract G. lucidum have the potential to be developed as anti-arthritis natural therapeutic.
Nuniek Ina Ratnaningtyas, Fajar Husen, Dalia Sukmawati, Eko Setio Wibowo, Arif Rahman Hikam, and Adil Aksoy
Journal of Pure and Applied Microbiology
Coprinus comatus (O.F. Mull.) Pers. is a medicinal and edible mushroom containing bioactive compounds known as antidiabetic and antioxidant agents. The pancreatic β-cells were sensitive to reactive oxygen species (ROS) attacks, which can cause necrosis and disrupt insulin production. Therefore, this research aimed to evaluate the C. comatus ethyl acetate extract for antidiabetic and antioxidant to decrease fasting blood glucose, dipeptidyl peptidase-4 enzyme (DPP-4) levels, and increase glutathione peroxidase (GPx). Subsequently, 24 male Wistar rats were divided into six groups, namely 2-5 streptozotocin (STZ)-induced 45 mg/kg, 1/HC (without any treatment), 2/NC (negative control), 3/PC (administered metformin 45 mg/kg Body weight (BW), 4-6 (T1: administered 250 mg, T2: administered 500 mg, and T3: administered 750 mg/kg BW extract). The parameters were analyzed using ANOVA, followed by Duncan’s multiple range test. According to the results, the extract significantly decreased DPP-4 levels, blood glucose and increased GPx (p ≤ 0.05). The 500 mg extract effectively reduced blood glucose levels and DPP-4 enzyme as well as increased levels of GPx.
Nuniek Ina Ratnaningtyas, Fajar Husen, Hernayanti Hernayanti, Nuraeni Ekowati, and Bambang Heru Budianto
Universitas Jenderal Soedirman

 
 
 oprinus comatus (O.F. Mull.) is an edible mushroom that is used as an anti-inflammatory agent. Therefore, this study aims to determine the effect of inflammation treatment on symptoms alleviating, function maintenance, and inhibiting the process of tissue damage due to an increase in free radicals using drug formulations with high antioxidant compounds. This is a true experiment conducted using a Completely Randomized Design (CRD) with a post-test and a control group. The rats were divided into 6 categories, which include 1 healthy and 5 groups induced with 1% carrageenan. Out of the treatment groups, 3 were treated with ethanol extract of C. comatus fruiting body at doses of 250 (T1), 500 (T2), and 750 mg/kg BW (T3), 1 received diclofenac sodium (PC) and the other as a negative control (NC), were given extract for 14 days and induced with 0.5 mL carrageenan in paw of rats at day 15. The qualitative identification showed the extracts contains flavonoid, polyphenol, alkaloid, triterpenoid, steroids and saponins, and GC-MS analysis showed 10 putative metabolites compound. T2 group significantly decreased the levels of IL-1β (70.63%), IgE (59.04%), total leukocyte count (31.24%), plantar thickness (12.5%), edema volume (33.3%), and increased endothelial NO levels (48.2%).
 
 
Fajar Husen, Nuniek Ina Ratnaningtyas, Siti Samiyarsih, Juni Safitri Muljowati, and Nur Fitrianto
Universitas Negeri Semarang
Soybean (Glycine max L. Merr.) is the third food crop commodity after rice and maize in Indonesia. This plant is also known as the most important source of vegetable protein, which is relatively inexpensive, but a decrease in soybean productivity can occur due to infection with disease-causing pathogens, one of is Cercospora kikuchii which causes Cercospora leaf blight (CLB). The research objectives were to determine the anatomical resistance and disease severity of soybean cultivars against CLB. The method was an experiment with a completely randomized design (CRD) factorial pattern; factor 1 being soybean cultivars (Dering, Slamet, Grobogan, Wilis) and factor 2, namely pathogen inoculation (0 conidiospores/mL and 105 conidiospores/mL). Anatomical method preparations using paraffin, staining with 1% safranin. Disease criteria are based on the council of scientific and industrial research (CSIR) assessment method. Data were analysis used analysis of variance (p0.05) and the least significance difference (LSD). The results showed that Dering and Slamet cultivars had the largest cuticle, epidermis, and palisade ratios and the smallest stomata length and width with the largest number of stomata and trichomes compared to Grobogan and Wilis. The disease severity (DS) of the cultivars Dering 14.6%, Slamet 24.64%, Grobogan 24.80% (classified as a resistant with low infection), while Wilis cultivar was 31.08% as a moderately susceptible cultivar with moderate infection. The novelty of soybean cultivar selection against CLB is important and its effectiveness for increasing soybean productivity. Dering, Slamet and Grobogan are likely to be further developed with their resistance to CLB disease.
Nuniek Ina Ratnaningtyas, Hernayanti Hernayanti, Nuraeni Ekowati, Fajar Husen, Isnaini Maulida, Riama Kustianingrum, and Vika Vidiyanti
Universitas Negeri Semarang
Coprinus comatus, well-known as Shaggy Ink Cap mushroom, is potential herbal medicine. Synthetic medicines sometimes cause side effects; therefore, it is necessary to innovate with herbal medications with minimal side effects. The study evaluated in vitro and in vivo treatments to evaluate the antioxidant effect and activity of C. comatus. The in vivo treatment was conducted using six groups of Wistar rats (n = 24). Group 1 healthy control (HC), groups 2–6 received 45 mg/Kg BW of streptozotocin once, group 2 just streptozotocin-induced (NC), group 3 was given 45 mg/kg BW of metformin (PC), groups 4–6 were given 250 (T1), 500 (T2), and 750 mg (T3) of C. comatus extract for 14 days, and the in vitro was conducted using an antioxidant oxidant assay. Data were analyzed using analysis of variance and Duncan's multiple range tests. Based on qualitative analysis, C. comatus mycelium extract contained polyphenol, flavonoids, terpenoids, and fruiting body extract had flavonoids, alkaloids, and saponins. The in vitro analysis showed that the mycelium extract had an antioxidant activity by inhibiting free radicals up to 58.51% with an IC50 value of 72.77 mg/L. The in vivo treatment using C. comatus fruiting body extract showed that it could increase the endogenous antioxidant levels of GPx, SOD, catalase and reduce MDA levels (p 0.05). The most effective dose of C. comatus extract is 500 mg. This research has shown the potential of mycelium and C. comatus fruitbody extract as an antioxidant supplement in a diabetic rat model.
N. I. Ratnaningtyas, Hernayanti Hernayanti, Nuraeni Ekowati and F. Husen
Abstract Context Edible mushrooms have a long history of use in traditional Chinese or Japanese medicine. Coprinus comatus (O.F. Müll.) Pers. (Agaricaceae) contains antioxidant and antidiabetic agents. Objective To identify the benefits of ethanol extracts of the C. comatus fruit body in streptozotocin-induced hyperglycaemic rats by evaluating their blood glucose, glycosylated haemoglobin (HbA1c), insulin, glucagon-like peptide-1 (GLP-1), dipeptidyl peptidase-4 (DPP-4), and glutathione (GSH) levels, with and without extract administration. Materials and methods Wistar rats were either left untreated or were administered 45 mg/kg body weight (BW) streptozotocin; 45 mg/kg BW metformin; or 250, 500, or 750 mg/kg BW extract for 14 days. The blood glucose, GLP-1, DPP-4, GSH, insulin, and HbA1c levels were determined. Data were analysed using analysis of variance and Duncan’s multiple range tests. Results Preliminary data showed that administration of C. comatus ethanol extract dose of 250, 500, and 750 mg orally has no toxicity effects after 24 h administration. The ethanolic extract of fruiting body of C. comatus considerably reduced the rat’s fasting blood glucose levels 26.69%, and DPP-4 6.97% at dose of 750 mg. The extract reduced HbA1c 4–4.30%, increased GLP-1 71.09%, GSH 11.19% at dose of 500 mg, and increased insulin levels 13.83%. Extracts contain bioactive compounds such as flavonoid, alkaloid, terpenoids, vitamins C and E, rutin, and saponin. Conclusions The C. comatus extract can be used as herbal medicine that reduces diabetic symptoms. Further investigation on C. comatus extracts should be conducted with gas chromatography-mass spectrometry to characterise the bioactive compounds.
N. I. Ratnaningtyas, Hernayanti, N. Ekowati and F. Husen
Diabetes mellitus (DM) is a metabolic disease with an increasing prevalence. An increase in free radicals and AGEs can cause glomerular cell damage which can lead to inflammation and DM nephropathy. WHO has recommended DM treatment by using herbal medicines that have minimal side effects and have a lot of biological activity to prevent complications. Coprinus comatus (O.F. Mull.) is known as immunomodulatory, anti-inflammatory and antidiabetic agent. The research used C. comatus cultivated in Cianjur. The basidiome of this mushroom has slightly oval and small with height of 8-12 cm and thickness of 2-3 cm. The research included six groups of male Wistar rats: Group 1 received no treatment, Groups 2–6 were administered 45 mg/kg BW streptozotocin once, Group 3 was administered 45 mg/kg BW metformin, Groups 4, 5, and 6 were administered 250, 500, and 750 mg/kg BW of C. comatus fruit body ethanol extract respectively for 14 days. The superoxide dismutase (SOD), malondialdehyde (MDA), hepcidin and β2 microglobulin (B2M) levels were evaluated. Data were analyzed using analysis of variance and Duncan’s multiple-range tests. The results showed that dose of 500 mg was effective in increasing SOD and decreasing hepcidin, B2M and MDA levels.
Fajar Husen, Hernayanti Hernayanti, Nuraeni Ekowati, Dalia Sukmawati, and Nuniek Ina Ratnaningtyas
Begell House
Coprinus comatus is known for its antihyperglycemic benefits. This study aimed to identify the effect of bioactive compounds of C. comatus extract as an antidiabetic agent linked to glucagon-like peptide 1 (GLP-1) and antioxidant properties in increasing glutathione (GSH) levels. This study used six groups of Wistar rats (n = 24). Group 1 comprised the healthy control. Groups 2-6 received 45 mg of streptozotocin/kg body weight (BW) once. Group 3 was also given 45 mg of metformin/kg BW, whereas groups 4-6 were also given 250, 500, and 750 mg of C. comatus ethyl acetate extract/kg BW for 14 days. Antidiabetic effects of alkaloids and saponin were seen in blood glucose and glycated hemoglobin (HbA1c) degradation, increased insulin, and increased inhibition of GLP-1 through dipeptidyl peptidase-4 activity. Flavonoid antioxidants, ascorbic acid (vitamin C), and α-tocopherol (vitamin E) are useful in protecting pancreatic в cells from free radicals. Data were analyzed using analysis of variance and Duncan's multiple range test. C. comatus ethyl acetate extract at doses of 250, 500, and 750 mg/kg BW worked as an antidiabetic and antioxidant agent that contained flavonoids (16.4 mg/L), alkaloids (2.97 mg/L), saponin, rutin (351.13 ppm), vitamin C (132.342 mg/L), and vitamin E (102.320 g/L). The 250-mg dose was effective in increasing insulin (8.11 mlU/mL) and reducing blood glucose (23.92%) and HbA1c (3.775%), whereas the 500-mg dose was effective in increasing levels of GLP-1 (1056.923 ng/L) and GSH (4.62 μmol/L).
RECENT SCHOLAR PUBLICATIONS
MOST CITED SCHOLAR PUBLICATIONS
RESEARCH OUTPUTS (PATENTS, SOFTWARE, PUBLICATIONS, PRODUCTS)
Effervescent of Mushroom Extracts